Rigel Pharmaceuticals (RIGL) Cost of Revenue (2018 - 2026)
Rigel Pharmaceuticals' quarterly Cost of Revenue came in at $4.6 million in Q1 2026, up 4.47% year-on-year from $4.4 million in Q1 2025, and down 22.65% quarter-over-quarter from $6.0 million in Q4 2025.
Rigel Pharmaceuticals has reported Cost of Revenue for 9 years, with the latest figure at $4.6 million in Q1 2026.
- For the quarter ending Q1 2026, Cost of Revenue rose 4.47% year-over-year to $4.6 million; the trailing twelve-month figure through Mar 2026 stood at $19.8 million (down 5.77% YoY), and the FY2025 full-year result was $19.6 million, up 5.22% from the prior year.
- Cost of Revenue for Q1 2026 stood at $4.6 million, down from $6.0 million in the prior quarter.
- The five-year high for Cost of Revenue was $8.0 million in Q3 2024, with the low at $121000.0 in Q1 2022.
- Average Cost of Revenue over 5 years is $3.0 million, with a median of $2.8 million recorded in 2024.
- Year-over-year, Cost of Revenue sank 61.71% in 2022 and jumped 1008.19% in 2023.
- Tracing RIGL's Cost of Revenue over 5 years: stood at $342000.0 in 2022, then jumped by 1008.19% to $3.8 million in 2023, then jumped by 52.74% to $5.8 million in 2024, then climbed by 2.87% to $6.0 million in 2025, then decreased by 22.65% to $4.6 million in 2026.
- The last three Cost of Revenue figures came in at $4.6 million (Q1 2026), $6.0 million (Q4 2025), and $4.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 392.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 296.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 207.52 Mn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 4.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.61 Mn |
| Mar 31, 2026 | 4.61 Mn |
| Dec 31, 2025 | 5.96 Mn |
| Dec 31, 2025 | 5.96 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Sep 30, 2025 | 4.75 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Mar 31, 2025 | 4.41 Mn |
| Dec 31, 2024 | 5.79 Mn |
| Dec 31, 2024 | 5.79 Mn |
| Sep 30, 2024 | 8.03 Mn |
| Sep 30, 2024 | 8.03 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Jun 30, 2024 | 2.81 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.03 Mn |
| Dec 31, 2023 | 3.79 Mn |
| Dec 31, 2023 | 3.79 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Sep 30, 2023 | 1.27 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 1.08 Mn |
| Mar 31, 2023 | 977,000.00 |
| Mar 31, 2023 | 977,000.00 |
| Dec 31, 2022 | 342,000.00 |
| Dec 31, 2022 | 342,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Sep 30, 2022 | 250,000.00 |
| Jun 30, 2022 | 1.04 Mn |
| Jun 30, 2022 | 1.04 Mn |
| Mar 31, 2022 | 121,000.00 |
| Mar 31, 2022 | 121,000.00 |
| Dec 31, 2021 | 487,000.00 |
| Dec 31, 2021 | 487,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Sep 30, 2021 | 151,000.00 |
| Jun 30, 2021 | 129,000.00 |
| Jun 30, 2021 | 129,000.00 |
| Mar 31, 2021 | 316,000.00 |
| Mar 31, 2021 | 316,000.00 |
| Dec 31, 2020 | 321,000.00 |
| Dec 31, 2020 | 321,000.00 |
| Sep 30, 2020 | 140,000.00 |
| Sep 30, 2020 | 140,000.00 |
| Jun 30, 2020 | 279,000.00 |
| Jun 30, 2020 | 279,000.00 |
| Mar 31, 2020 | 155,000.00 |
| Mar 31, 2020 | 155,000.00 |
| Dec 31, 2019 | 178,000.00 |
| Dec 31, 2019 | 178,000.00 |
| Sep 30, 2019 | 310,000.00 |
| Sep 30, 2019 | 310,000.00 |
| Jun 30, 2019 | 311,000.00 |
| Jun 30, 2019 | 311,000.00 |
| Mar 31, 2019 | 107,000.00 |
| Mar 31, 2019 | 107,000.00 |
| Dec 31, 2018 | 188,000.00 |
| Dec 31, 2018 | 188,000.00 |
| Sep 30, 2018 | 69,000.00 |
| Sep 30, 2018 | 69,000.00 |
| Jun 30, 2018 | 30,000.00 |
| Jun 30, 2018 | 30,000.00 |